Patents by Inventor Jin-Chen Yu

Jin-Chen Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-FRa ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
    Publication number: 20250059274
    Abstract: Disclosed is an antibody that specifically recognizes and binds to folate receptor ?, also referred to as anti-folate receptor a antibody or anti-FR? antibody. Also disclosed is an antibody-drug conjugate of the anti-FR? antibody. Disclosed are uses of the anti-FR? antibody and the antibody-drug conjugate in the treatment of diseases related to FR? expression.
    Type: Application
    Filed: December 23, 2022
    Publication date: February 20, 2025
    Inventors: Weijia TANG, Siqi MAI, Xin ZHOU, Hui YAN, Shuoxu LI, Jianjun FAN, Jingyi SHEN, Shide LIANG, Jin-Chen YU, Shengfeng LI
  • USE OF ANTI-PD-L1/CD47 BISPECIFIC ANTIBODY IN TREATMENT OF DISEASES
    Publication number: 20250051450
    Abstract: The present invention discloses use of an anti-PD-L1/CD47 bispecific antibody in the treatment of a disease. A treatment method comprises administering to a patient in need thereof an effective amount of an anti-PD-L1/CD47 bispecific antibody or an antigen-binding fragment.
    Type: Application
    Filed: August 5, 2022
    Publication date: February 13, 2025
    Applicant: BIO-THERA SOLUTIONS, LTD.
    Inventors: Yifan Chen, Ziyi Fu, Qiulian Liang, Jin-Chen Yu, Shengfeng Li
  • ANTI-B7-H3 ANTIBODY AND APPLICATION THEREOF
    Publication number: 20240400690
    Abstract: Disclosed is an anti-B7-H3 antibody and application of an anti-B7-H3 antibody. The anti-B7-H3 antibody or an antigen-binding fragment can specifically bind to B7-H3. The anti-B7-H3 antibody or an antigen-binding fragment has high affinity and strong internalization capability, and can be used for the diagnosis and/or treatment of tumors (including cancers and benign tumors).
    Type: Application
    Filed: September 29, 2022
    Publication date: December 5, 2024
    Inventors: Huafei SU, Yuting ZHONG, Jinchan LIANG, Shide LIANG, Jin-chen YU, Shengfeng LI
  • DRUG CONJUGATE AND USE THEREOF
    Publication number: 20240269315
    Abstract: A drug conjugate, such as an antibody drug conjugate, and the use thereof, belonging to the field of biomedicine. In some embodiments, the drug conjugate is a compound of Formula I or a pharmaceutically acceptable salt or a solvate thereof, and can be used for treating cancers, autoimmune diseases, inflammatory diseases or infectious diseases.
    Type: Application
    Filed: June 1, 2022
    Publication date: August 15, 2024
    Inventors: Weijia TANG, Xin ZHOU, Xingxing MEI, Hui YAN, Shuoxu LI, Jianjun FAN, Xuekang QI, Jin-Chen YU, Shengfeng LI
  • ANTI-CLDN18.2 ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20240092892
    Abstract: The present invention relates to the field of bio-pharmaceuticals and provides an anti-CLDN18.2 antibody. Related preparation methods and related uses are described. The antibody of the present invention or related an antigen-binding fragment can specifically bind to CLDN18.2 with a strong binding capacity. After humanization, the antibody or the antigen-binding fragment has a strong ADCC effect and CDC activity and has good pharmaceutical prospects.
    Type: Application
    Filed: December 29, 2021
    Publication date: March 21, 2024
    Inventors: Chao QIN, Cuizhen XIAO, Jin-Chen YU, Shengfeng LI
  • BISPECIFIC ANTIBODY AND USE THEREOF
    Publication number: 20240067728
    Abstract: The present invention provides a bispecific antibody and use thereof, and the bispecific antibody or an antigen-binding fragment of the present invention can bind to two or more antigens or two or more epitopes of a same antigen. The antibody or the antigen-binding fragment of the present invention can be used to treat a variety of diseases, such as inflammatory diseases, autoimmune diseases, cancers or spinal cord injury, and can also be used for diagnosis and prognosis of related diseases.
    Type: Application
    Filed: November 5, 2021
    Publication date: February 29, 2024
    Inventors: Yifan CHEN, Qiulian LIANG, Shujun PEI, Jin-Chen YU, Shengfeng LI
  • USE OF ANTI-PD-1 ANTIBODY IN COMBINATION THERAPY
    Publication number: 20240002511
    Abstract: Disclosed are anti-PD-1 antibodies and use of an anti-PD-1 antibody in a combination therapy. Treatment methods are disclosed and include administering to a patient in need an effective amount of an anti-PD-1 antibody and a therapeutic agent. Methods for treating a tumor or cancer using anti-PD-1 antibody and a therapeutic agent are disclosed.
    Type: Application
    Filed: October 9, 2021
    Publication date: January 4, 2024
    Inventors: Haitao YUE, Shujun PEI, Ziqi SU, Weijia TANG, Jin-Chen YU, Shengfeng LI
  • USE OF ANTI-OX40 ANTIBODY IN TREATMENT OF TUMOR OR CANCER
    Publication number: 20230416386
    Abstract: The use of an anti-OX40 antibody or an antigen-binding fragment in the treatment of a tumor or cancer, is described. Also described is a treatment method of a tumor or cancer and includes administering to a patient in need an effective amount of an anti-OX40 antibody or an antigen-binding fragment. Kits including an anti-OX40 antibody or an antigen-binding fragment are also described.
    Type: Application
    Filed: November 18, 2021
    Publication date: December 28, 2023
    Applicant: Bio-Thera Solutions, Ltd.
    Inventors: Shizhong LIANG, Binghui LIANG, Jin-Chen YU, Xiao LI, Shuqiang SONG, Shengfeng LI
  • ANTI-CD20 ANTIBODY FORMULATION AND USE OF ANTI-CD20 ANTIBODY FOR TREATMENT OF CD20 POSITIVE DISEASES
    Publication number: 20230338526
    Abstract: Disclosed are anti-CD20 antibody formulations and use of anti-CD20 antibodies for the treatment of CD20 positive diseases, such as methods of using anti-CD20 antibodies for treating CD20 positive diseases, such as neuromyelitis optica spectrum disorders (NMOSD), non-Hodgkin's lymphoma (NHL), multiple sclerosis (MS), immune thrombocytopenia (ITP), rheumatoid arthritis (RA), Wegener's granulomatosis (WG), microscopic polyangiitis (MPA), lupus nephritis, systemic lupus erythematosus and chronic lymphocytic leukemia (CLL).
    Type: Application
    Filed: October 12, 2020
    Publication date: October 26, 2023
    Inventors: Yanyu CHEN, Yong WU, Yuanqing ZHOU, Chao QIN, Cuizhen XIAO, Zhihao WU, Dandan HUANG, Yujie LIU, Shengwu WANG, Cuihua LIU, Yunpeng QI, Jin-Chen YU, Li ZHANG, Shengfeng LI
  • ANTI-CD47 ANTIBODY AND USE THEREOF
    Publication number: 20230303711
    Abstract: CD47 antibodies and use thereof are disclosed, particularly to monoclonal antibodies that recognize CD47, and more particularly to CD47 antibodies that do not cause significant levels of hemagglutination, red blood cell reduction and platelet reduction, and to a method for preparing these antibodies and use of these monoclonal antibodies in the manufacture of medicaments for treating cancer or infection.
    Type: Application
    Filed: July 30, 2021
    Publication date: September 28, 2023
    Inventors: Xianqin LIU, Jingyi SHEN, Weijia TANG, Jin-Chen YU, Shengfeng LI
  • ANTI-PD-L1 ANTIBODY AND USE THEREOF
    Publication number: 20230287126
    Abstract: Disclosed are anti-PD-L1 antibodies and use of anti-PD-1 antibodies. The antibody or the antigen-binding fragment can specifically bind to PD-L1 and block the interaction between PD-1 and PD-L1. The antibody or the antigen-binding fragment can help the immune system to clear tumor cells, and can also be used for the diagnosis and prognosis of a tumor or a cancer.
    Type: Application
    Filed: August 6, 2021
    Publication date: September 14, 2023
    Inventors: Yifan CHEN, Qiulian LIANG, Jin-Chen YU, Shengfeng LI
  • ANTI-HER2 ANTIBODY AND USE THEREOF
    Publication number: 20230279144
    Abstract: The present invention provides an anti-HER2 antibody and use thereof, wherein the antibody provided by the present invention can be used for the treatment of HER2-positive diseases, and can also be used for the diagnosis and prognosis of HER2-positive diseases. The Antibody BAT0303F disclosed herein is expressed by a host cell with fucosyltransferase knocked out, and can enhance ADCC effect of the antibody.
    Type: Application
    Filed: July 27, 2021
    Publication date: September 7, 2023
    Inventors: Xingxing MEI, Weijia TANG, Jin-Chen YU, Cuiying FENG, Yujie LIU
  • ANTI-CTLA-4 MONOCLONAL ANTIBODY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
    Publication number: 20230203164
    Abstract: Disclosed is an anti-CTLA-4 monoclonal antibody and a preparation and use thereof. The anti-CTLA-4 antibody has the advantages of lower toxicity and better activity; in addition, the anti-CTLA-4 antibody also has a low content of high mannose glycoforms and/or a low content of sialylated glycoforms, which helps to prolong the half-life of the antibody and/or reduce immunogenicity. In addition, disclosed is a formulation with the antibody which has good stability.
    Type: Application
    Filed: December 25, 2020
    Publication date: June 29, 2023
    Inventors: Ziqi SU, Chao QIN, Jin-Chen YU, Dandan HUANG, Yong WU, Di CAO, Cuihua LIU, Shuqiang SONG, Shengfeng LI
  • DEVELOPMENT AND APPLICATION OF IMMUNE CELL ACTIVATOR
    Publication number: 20230139700
    Abstract: The development and use of an anti-OX40 antibody and immune cell activation is disclosed. The anti-OX40 antibody or a fragment of the anti-OX40 antibody retains strong binding to human OX40 or Rhesus Monkey OX40. The anti-OX40 antibody or a fragment of the anti-OX40 antibody more effectively activates T cells, generates stronger immune responses, and improves anti-tumor activity.
    Type: Application
    Filed: March 22, 2021
    Publication date: May 4, 2023
    Applicant: Bio-Thera Solutions, Ltd.
    Inventors: Shizhong LIANG, Dandan ZHENG, Jin-Chen YU, Shengfeng LI
  • ANTI-TIGIT IMMUNOSUPPRESSANT AND APPLICATION THEREOF
    Publication number: 20220348650
    Abstract: The present invention provides an anti-TIGIT immunosuppressant and use thereof. The immunosuppressant can bind to the extracellular region of human TIGIT, and can be used for treating diseases such as a cancer.
    Type: Application
    Filed: September 3, 2020
    Publication date: November 3, 2022
    Inventors: Junjie Huang, Xiaoyun Wu, Zhenqian Xu, Shide Liang, Shengfeng Li, Jin-Chen Yu, Xianming Huang
  • Compounds and methods for the treatment of TROP2 positive diseases
    Patent number: 11192954
    Abstract: The present invention generally relates to compounds comprising antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to TROP2 (TACSTD2). The present invention also relates to methods of using such TROP2-binding molecules for diagnosing and treating diseases, such as malignancies.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: December 7, 2021
    Assignee: Bio-Thera Solutions, Ltd.
    Inventors: Weijia Tang, Xiaoyang Huang, Jin-Chen Yu, Ziqiang Ou, Xian Peng, Yili Yang, Shengfeng Li, Chao Qin
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF TROP2 POSITIVE DISEASES
    Publication number: 20190048095
    Abstract: The present invention generally relates to compounds comprising antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to TROP2 (TACSTD2). The present invention also relates to methods of using such TROP2-binding molecules for diagnosing and treating diseases, such as malignancies.
    Type: Application
    Filed: August 10, 2018
    Publication date: February 14, 2019
    Applicant: BIO-THERA SOLUTIONS, LTD.
    Inventors: Weijia TANG, Xiaoyang HUANG, Jin-Chen YU, Ziqiang OU, Xian PENG, Yili YANG, Shengfeng LI, Chao QIN
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES
    Publication number: 20170258935
    Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.
    Type: Application
    Filed: May 26, 2017
    Publication date: September 14, 2017
    Applicant: Bio-Thera Solutions, Ltd., Co.
    Inventors: Weijia Tang, Shengfeng Li, Jin-Chen Yu, Xiaobin Deng
  • Compounds and methods for the treatment of ERB B2/NEU positive diseases
    Patent number: 9737616
    Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: August 22, 2017
    Assignee: Bio-Thera Solutions, Ltd., Co.
    Inventors: Weijia Tang, Shengfeng Li, Jin-Chen Yu, Xiaobin Deng
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES
    Publication number: 20150320881
    Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.
    Type: Application
    Filed: July 17, 2015
    Publication date: November 12, 2015
    Applicant: BIO-THERA SOLUTIONS, LTD., CO.
    Inventors: Weijia Tang, Shengfeng Li, Jin-Chen Yu, Xiaobin Deng